Latest research on Welchol

Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.

Welchol indications

The GLOWS (Glucose-Lowering Effect of Welchol) study was a prospective, double-blind, placebo-controlled, parallel design, add-on trial in which 65 less than optimally controlled type 2 DM patients (mean HbA1c 7.9%; mean fasting blood sugar [FBS] 170 mg/dL; mean 1-hour postprandial glucose 269 mg/dL), being treated with sulfonylurea and/or Metformin, were randomized to receive either colesevelam 3.8 g/day or placebo. [source, 2012]
A pilot study, GLOWS (Glucose-Lowering effect of Welchol Study), showed that colesevelam significantly reduced LDL-C levels (11.7%) and HbA1c (0.5%) compared with placebo when added to existing metformin- and/or sulfonylurea-based therapy in patients with type 2 diabetes [76]. [source, 2010]
ACC: American College of Cardiology; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADA: American Diabetes Association; Apo: apolipoprotein; ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm; ASPEN: Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus; BP: blood pressure; CARDS: Collaborative Atorvastatin Diabetes Study; CETP: cholesterol ester transfer protein; CHD: coronary heart disease; CVD: cardiovascular disease; EUROASPIRE: EUROpean Action on Secondary Prevention through Intervention to Reduce Events; FIELD: Fenofibrate Intervention and Event Lowering in Diabetes; FXR: farnesoid X receptor; GLOWS: Glucose-Lowering effect of Welchol Study; GLP-1: glucagon-like peptide-1; HDL-C: high-density lipoprotein cholesterol; HPS: Heart Protection Study; IDL: intermediate-density lipoprotein; LDL-C: low-density lipoprotein cholesterol; NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel III; NEFA: nonesterified (free) fatty acid; NHANES: United States National Health and Nutritional Examination Survey; NMR: nuclear magnetic resonance; Non-HDL-C: non-high-density lipoprotein cholesterol; RAAS: renin-angiotensin-aldosterone system; SHIELD: Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes; TC: total cholesterol; TG: triglyceride; TNT: Treating to New Targets; UKPDS: United Kingdom Prospective Diabetes Study; VLDL: very-low-density lipoprotein cholesterol. [source, 2010]
Human drug interaction studies with colesevelam HCl have found no significant effect on the bioavailability of Digoxin, Fenofibrate, LOVASTATIN, Metoprolol, Quinidine, VALPROIC acid, warfarin, or statins (Welchol). [source, 2007]
However, the common BAS Cholestyramine resin (Locholest, Questran), Colesevelam (Welchol), and Colestipol (Colestid) are known to exhibit major adverse effects [19]. [source, 2004]